Perrigo Company plc (PRGO)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 3
Do Nothing: qualitativeScore is 2 (below the required floor of 3); the strategy requires qualitativeScore >= 3 before any bullish entry, and no chart pattern overrides that floor. The block is entry-type independent, so neither a pullback limit nor a breakout stop was evaluated for construction. Technicals were fully computed (technicalScore 3 — a pullback-within-uptrend stabilization chart) and are preserved for reference.
Company overview
Perrigo Company plc provides over-the-counter health and wellness solutions globally, operating through its Consumer Self-Care Americas and International segments. The company offers a range of products including respiratory, nutrition, digestive health, pain relief, oral care, and women's health products, among others. It sells its products under various brand names and through multiple retail channels.
Fundamental
fairPerrigo's fundamentals show positive cash flow but are weighed down by solvency concerns and recent gross-margin pressure.
SEC filings show that FY2025 results were dominated by a large goodwill impairment tied to weaker expectations in parts of the portfolio (notably infant formula), which drove a very large GAAP loss and pushed EBIT/EBITDA negative. Importantly, operating cash flow stayed positive and the latest 10-Q shows adequate liquidity (cash around $400M plus a $1B revolver extended to 2031) with covenant compliance, suggesting no near-term going-concern stress. That said, sales have drifted down from 2023 levels and the latest quarter shows gross-margin compression and softer core adjusted earnings, so an underlying operating turn is not yet fully proven in GAAP run-rate terms. Leverage remains a key overhang: total debt is still around $3.3B and the Altman Z-Score sits deep in the distress zone, while interest coverage is only modest. Valuation looks inexpensive on EV/Sales and free-cash-flow yield, but earnings-based multiples are not meaningful with negative GAAP earnings and the DCF outputs appear implausibly high versus the share price, so valuation signals should be treated cautiously. Overall, this reads as a cash-generative but still-risky turnaround/deleveraging situation rather than a clean high-quality compounder.
Sentiment
weakNo dominant near-term catalyst exists, with sentiment and retail interest too thin to establish a trend.
No dominant near-term catalyst exists: the Q2 2026 EPS beat (Aug 5) is 45 days back and fully priced, and the last two weeks brought only routine disclosures, consensus recaps, and a 200-day MA cross. The sentiment delta is indeterminate (sparse baseline, 2 scored items) against a mildly positive 14-day window (aggregate polarity_score ≈ +0.075 across 4 aggregator-tier items), retail is silent, and the Red-Flag Screen shows no severe or moderate flags — a quiet, absent setup.
Technical
fairThe stock is stabilizing within an uptrend but lacks momentum confirmation, with mixed technical indicators.
Trend frame: close 13.56 vs SMA20 14.17 (below), SMA50 12.53 (above), SMA200 12.23 (above), EMA9 13.74 (below), EMA21 13.71 (below), daily VWAP 13.46 (above). Momentum: RSI14 50.10 neutral, Williams %R -78.26 near oversold, MACD 0.21/0.43 with histogram -0.22 (fading), ADX14 30.95 — trend strength high but the recent directional move is down from the 09-04 high. Volatility: ATR14 0.57 (4.20% of price), StdDev20 0.46. Volume: avgDollarVolume20 $38.04M vs the $5M floor (pass); recent 3-session regular-session dollar volume averaged ~$27.8M vs the $1.5M recent-liquidity floor (pass); 09-18 was a high-volume up day off the low. Events: confirmed earnings 2026-11-04 (Q3 FY2026, BMO, EPS est 0.517) — far outside the +/-3 trading-day entry blackout and outside the 15-trading-day holding window (horizon 2026-10-09), no block; dividend calendar returned no events in 2026-08-20..2026-12-18, so neither the 1.5% dividend blackout nor the holding-window dividend gate applies; no splits in the past 30d or next 90d. Overnight-gap gate: max regular-session overnight gap 1.55% over the last 5 sessions — well under the 5% threshold (pass); primary price discovery is clearly US regular-hours. The chart visually resembles a pullback_to_support stabilization within an uptrend, but the structured verdict is no_setup: the qualitative override gate (qualitativeScore 2 < 3) blocks every entry type — limit or stop — identically, so the trade plan was not constructed and entry-construction rules were not reached.
In-depth analysis
Valuation
- PE ratio is not meaningful due to negative earnings.
- EV/EBITDA is not meaningful due to negative EBITDA.
- The EV/Sales ratio suggests the stock is relatively inexpensive compared to its sales.
- PEG is not meaningful as EPS growth is zero.
- The free cash flow yield is strong, indicating attractive cash generation relative to the stock price.
Profitability
- ROIC is low, indicating limited returns on invested capital.
- EBITDA margin is not meaningful due to negative EBITDA.
- Net margin is not meaningful due to negative earnings.
- Gross margin is moderate, reflecting average cost management.
- ROE is not meaningful due to negative earnings.
Growth
- Revenue growth is slow, indicating limited top-line expansion.
- EPS growth is flat, reflecting stagnation in earnings per share.
- EBITDA growth is flat, indicating no improvement in operating profitability.
Risk
- Net debt to EBITDA is not meaningful due to negative EBITDA.
- The current ratio is strong, indicating good short-term liquidity.
- The beta is low, suggesting lower volatility compared to the market.
- The Z-score indicates financial distress, highlighting solvency concerns.
- Interest coverage is low, suggesting limited ability to cover interest expenses.
Discounted Cash Flow
Callout
The DCF model outputs imply very large upside, but these should be treated with caution due to abnormal GAAP results and low confidence until earnings normalize.
Trade plan
- Entry
- 0.00
- Protective stop
- 0.00
- Reward : risk
- 0.00 : 1
You’re looking at 2026-09-19 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

